Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neur… Read more
Alzamend Neuro Inc (ALZN) - Total Liabilities
Latest total liabilities as of October 2025: $717.49K USD
Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has total liabilities worth $717.49K USD as of October 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alzamend Neuro Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Alzamend Neuro Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Alzamend Neuro Inc Competitors by Total Liabilities
The table below lists competitors of Alzamend Neuro Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TMT Investments PLC
LSE:TMT
|
UK | $661.36K |
|
Danel (Adir Yeoshua) Ltd
TA:DANE
|
Israel | ILA838.21 Million |
|
Noram Lithium Corp
OTCQB:NRVTF
|
USA | $1.19 Million |
|
UCAL Limited
NSE:UCAL
|
India | ₹4.93 Billion |
|
Mudajaya Group Bhd
KLSE:5085
|
Malaysia | RM1.14 Billion |
|
The Steel Public Company Limited
BK:THE
|
Thailand | ฿1.80 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Alzamend Neuro Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alzamend Neuro Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alzamend Neuro Inc (2016–2025)
The table below shows the annual total liabilities of Alzamend Neuro Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $634.76K | -80.32% |
| 2024-04-30 | $3.23 Million | +12.39% |
| 2023-04-30 | $2.87 Million | +146.38% |
| 2022-04-30 | $1.16 Million | +29.49% |
| 2021-04-30 | $899.64K | -9.34% |
| 2020-04-30 | $992.31K | -16.19% |
| 2019-04-30 | $1.18 Million | +1124.10% |
| 2018-04-30 | $96.72K | -86.51% |
| 2017-04-30 | $717.22K | +2234.71% |
| 2016-04-30 | $30.72K | -- |